Combination chemotherapy with temozolomide, lomustine, vincristine and interferon-alpha (TOL-IFN) plus vemurafenib or TOL-IFN as first-line treatment for patients with advanced melanoma

References

• Eggermont AM, Robert C. New drugs in melanoma: it's a whole new world. Eur J Cancer. 2011;47(14):2150–2157.
   PubMed Web of Science ®Google Scholar
• Yang AS, Chapman PB. The history and future of chemotherapy for melanoma. Hematol Oncol Clin North Am. 2009;23(3):583–597. x. Epub 2009/05/26.
   PubMed Web of Science ®Google Scholar
• Bajetta E, Del Vecchio M, Bernard-Marty C, et al. Metastatic melanoma: chemotherapy. Semin Oncol. 2002;29(5):427–445.
   PubMed Web of Science ®Google Scholar
• Legha SS, Ring S, Eton O, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998;16(5):1752–1759.
   PubMed Web of Science ®Google Scholar
• Pyrhonen S, Hahka-Kemppinen M, Muhonen T. A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol. 1992;10(12):1919–1926.
   PubMed Web of Science ®Google Scholar
• Mattila K, Raanta P, Lahtela V, et al. Long-term survival of stage IV melanoma patients treated with BOLD combination chemotherapy and intermediate-dose subcutaneous interferon-alpha. Anticancer Res. 2018;38(11):6393–6397.
   PubMed Web of Science ®Google Scholar
• Hodi FS, Chiarion-Sileni V, Gondalez R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480–1492.
   PubMed Web of Science ®Google Scholar
• Long GV, Flaherty KT, Stroyakovski D, et al. Dabrafenib plus trametinib versus dabreafenib monotherapy in patients with metastastic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study. Ann Oncol. 2017;28(7):1631–1639.
   PubMed Web of Science ®Google Scholar
• Drummer R, Ascierto PA, Gogas HJ, et al. Overall survival in patients with BRAF-mutant melanoma receiveing encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018;19:1315–1327.
   PubMed Web of Science ®Google Scholar
• Tawbi HA, Forsyth PA, Algazi A, et al. Combined nivolumab and ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379(8):722–730.
   PubMed Web of Science ®Google Scholar
• Davies MA, Saiag P, Robert C, et al. Dabrafenib plus trametinib in patients with BRAFv600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18(7):863–873.
   PubMed Web of Science ®Google Scholar
• Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
   PubMed Web of Science ®Google Scholar
• Common Terminology Criteria for Adverse Events (CTCAE)-EORTC. [cited 2019 Sep 19]. Available from: https://www.eortc.be/services/doc/ctc/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf
   Google Scholar
• Agarwala SS, Kirkwood JM, Gore M, et al. Temozolomide for the Treatment of brain metastases associated with metastatic melanoma: a phase II study. J Clin Oncol. 2004;22(11):2101–2107.
   PubMed Web of Science ®Google Scholar
• Van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J Clin Oncol. 2013;31(3):344–350.
   PubMed Web of Science ®Google Scholar
• Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high‐grade glioma. J Clin Oncol. 2010;28(30):4601–4610.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Van Akkooi A, Berking C, et al. Melanoma. Lancet. 2018;392(10151):971–984.
   PubMed Web of Science ®Google Scholar
• Vuoristo MS, Hahka-Kemppinen M, Parvinen LM, et al. Randomized trial of dacarbazine versus bleomycin, vincristine, lomustine and dacarbazine (BOLD) chemotherapy combined with natural or recombinant interferon-alpha in patients with advanced melanoma. Melanoma Res. 2005;15(4):291–296.
   PubMed Web of Science ®Google Scholar